| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
University Department of Medicine, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia 6009
The role of tumor-specific CD8 and CD4 lymphocytes in rejecting solid tumors has been difficult to determine because of the lack of models in which tumor antigen, specific CD8 cells, and specific CD4 cells can be monitored and controlled. To investigate the minimal components required for the induction and maintenance of CTL activity sufficient to reject a solid tumor in vivo, we transfected the influenza hemagglutinin (HA) gene into a nonimmunogenic class I+/class II- murine malignant mesothelioma (MM) tumor line to generate an endogenous tumor antigen and used TCR transgenic mice with class I- or class II-restricted specificities for HA as sources of naive, tumor-specific T cells. The data show that the presence of a strong tumor antigen is not in itself sufficient to induce an effective CTL response, nor does the presence of a high frequency of precursor cells guarantee tumor rejection. We also show that tumor-specific CD4 cells, when CTL numbers are suboptimal, greatly enhance the eradication of tumor, confirming the importance of antigen-presenting cell presentation of tumor antigens to class II-restricted cells. These data confirm that T-cell receptor transgenic cells, combined with nominal tumor antigen transfection, represent powerful tools to analyze tumor-specific T-cell responses.
This article has been cited by other articles:
|
|
 |
|
  M. J. Smyth, M. W.L. Teng, J. Sharkey, J. A. Westwood, N. M. Haynes, H. Yagita, K. Takeda, P. V. Sivakumar, and M. H. Kershaw Interleukin 21 Enhances Antibody-Mediated Tumor Rejection Cancer Res., April 15, 2008; 68(8): 3019 - 3025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Currie, R. G. van der Most, S. A. Broomfield, A. C. Prosser, M. G. Tovey, and B. W. S. Robinson Targeting the Effector Site with IFN-{alpha}{beta}-Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors J. Immunol., February 1, 2008; 180(3): 1535 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Kousis, B. W. Henderson, P. G. Maier, and S. O. Gollnick Photodynamic Therapy Enhancement of Antitumor Immunity Is Regulated by Neutrophils Cancer Res., November 1, 2007; 67(21): 10501 - 10510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Matter, V. Pavelic, D. D. Pinschewer, S. Mumprecht, B. Eschli, T. Giroglou, D. von Laer, and A. F. Ochsenbein Decreased Tumor Surveillance after Adoptive T-Cell Therapy Cancer Res., August 1, 2007; 67(15): 7467 - 7476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Odunsi, F. Qian, J. Matsuzaki, P. Mhawech-Fauceglia, C. Andrews, E. W. Hoffman, L. Pan, G. Ritter, J. Villella, B. Thomas, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer PNAS, July 31, 2007; 104(31): 12837 - 12842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rudge, S. P. Barrett, B. Scott, and I. R. van Driel Infiltration of a Mesothelioma by IFN-{gamma}-Producing Cells and Tumor Rejection after Depletion of Regulatory T Cells J. Immunol., April 1, 2007; 178(7): 4089 - 4096. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. McWilliams, S. M. McGurran, S. W. Dow, J. E. Slansky, and R. M. Kedl A Modified Tyrosinase-Related Protein 2 Epitope Generates High-Affinity Tumor-Specific T Cells but Does Not Mediate Therapeutic Efficacy in an Intradermal Tumor Model J. Immunol., July 1, 2006; 177(1): 155 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Chamoto, D. Wakita, Y. Narita, Y. Zhang, D. Noguchi, H. Ohnishi, T. Iguchi, T. Sakai, H. Ikeda, and T. Nishimura An Essential Role of Antigen-Presenting Cell/T-Helper Type 1 Cell-Cell Interactions in Draining Lymph Node during Complete Eradication of Class II-Negative Tumor Tissue by T-Helper Type 1 Cell Therapy Cancer Res., February 1, 2006; 66(3): 1809 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. N. Hwang, Z. Yu, D. C. Palmer, and N. P. Restifo The In vivo Expansion Rate of Properly Stimulated Transferred CD8+ T Cells Exceeds That of an Aggressively Growing Mouse Tumor Cancer Res., January 15, 2006; 66(2): 1132 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Broomfield, A. Currie, R. G. van der Most, M. Brown, I. van Bruggen, B. W.S. Robinson, and R. A. Lake Partial, but not Complete, Tumor-Debulking Surgery Promotes Protective Antitumor Memory when Combined with Chemotherapy and Adjuvant Immunotherapy Cancer Res., September 1, 2005; 65(17): 7580 - 7584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Benigni, V. S. Zimmermann, S. Hugues, S. Caserta, V. Basso, L. Rivino, E. Ingulli, L. Malherbe, N. Glaichenhaus, and A. Mondino Phenotype and Homing of CD4 Tumor-Specific T Cells Is Modulated by Tumor Bulk J. Immunol., July 15, 2005; 175(2): 739 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Stumbles, R. Himbeck, J. A. Frelinger, E. J. Collins, R. A. Lake, and B. W. S. Robinson Cutting Edge: Tumor-Specific CTL Are Constitutively Cross-Armed in Draining Lymph Nodes and Transiently Disseminate to Mediate Tumor Regression following Systemic CD40 Activation J. Immunol., November 15, 2004; 173(10): 5923 - 5928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tanaka, S. Koido, J. Xia, M. Ohana, C. Liu, G. M. Cote, D. B. Sawyer, S. Calderwood, and J. Gong Development of Antigen-Specific CD8+ CTL in MHC Class I-Deficient Mice through CD4 to CD8 Conversion J. Immunol., June 15, 2004; 172(12): 7848 - 7858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Friedman, C. S. Bangur, E. J. Zasloff, L. Fan, T. Wang, Y. Watanabe, and M. Kalos Molecular and Immunological Evaluation of the Transcription Factor SOX-4 as a Lung Tumor Vaccine Antigen J. Immunol., March 1, 2004; 172(5): 3319 - 3327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Nowak, B. W. S. Robinson, and R. A. Lake Synergy between Chemotherapy and Immunotherapy in the Treatment of Established Murine Solid Tumors Cancer Res., August 1, 2003; 63(15): 4490 - 4496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Nowak, R. A. Lake, A. L. Marzo, B. Scott, W. R. Heath, E. J. Collins, J. A. Frelinger, and B. W. S. Robinson Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells J. Immunol., May 15, 2003; 170(10): 4905 - 4913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Cho, M. Miyamoto, K. Kato, A. Fukunaga, T. Shichinohe, Y. Kawarada, Y. Hida, T. Oshikiri, T. Kurokawa, M. Suzuoki, et al. CD4+ and CD8+ T Cells Cooperate to Improve Prognosis of Patients with Esophageal Squamous Cell Carcinoma Cancer Res., April 1, 2003; 63(7): 1555 - 1559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Huang, F. Li, J. R. Gordon, and J. Xiang Synergistic Enhancement of Antitumor Immunity with Adoptively Transferred Tumor-specific CD4+ and CD8+ T Cells and Intratumoral Lymphotactin Transgene Expression Cancer Res., April 1, 2002; 62(7): 2043 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Nowak, B. W. S. Robinson, and R. A. Lake Gemcitabine Exerts a Selective Effect on the Humoral Immune Response: Implications for Combination Chemo-immunotherapy Cancer Res., April 1, 2002; 62(8): 2353 - 2358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Nelson, S. Mukherjee, C. Bundell, S. Fisher, D. van Hagen, and B. Robinson Tumor Progression Despite Efficient Tumor Antigen Cross-Presentation and Effective "Arming" of Tumor Antigen-Specific CTL J. Immunol., May 1, 2001; 166(9): 5557 - 5566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Eck and L. A. Turka Adoptive Transfer Enables Tumor Rejection Targeted against a Self-Antigen without the Induction of Autoimmunity Cancer Res., April 1, 2001; 61(7): 3077 - 3083. [Abstract] [Full Text]
|
|
|
|
|
|
N. Dalyot-Herman, O. F. Bathe, and T. R. Malek Reversal of CD8+ T Cell Ignorance and Induction of Anti-Tumor Immunity by Peptide-Pulsed APC J. Immunol., December 15, 2000; 165(12): 6731 - 6737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Marzo, B. F. Kinnear, R. A. Lake, J. J. Frelinger, E. J. Collins, B. W. S. Robinson, and B. Scott Tumor-Specific CD4+ T Cells Have a Major ""Post-Licensing"" Role in CTL Mediated Anti-Tumor Immunity J. Immunol., December 1, 2000; 165(11): 6047 - 6055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Nelson, C. Bundell, and B. Robinson In Vivo Cross-Presentation of a Soluble Protein Antigen: Kinetics, Distribution, and Generation of Effector CTL Recognizing Dominant and Subdominant Epitopes J. Immunol., December 1, 2000; 165(11): 6123 - 6132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. von Mehren, P. Arlen, K. Y. Tsang, A. Rogatko, N. Meropol, H. S. Cooper, M. Davey, S. McLaughlin, J. Schlom, and L. M. Weiner Pilot Study of a Dual Gene Recombinant Avipox Vaccine Containing Both Carcinoembryonic Antigen (CEA) and B7.1 Transgenes in Patients with Recurrent CEA-expressing Adenocarcinomas Clin. Cancer Res., June 1, 2000; 6(6): 2219 - 2228. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Robinson, M. Callow, S. Stevenson, B. Scott, B. W. S. Robinson, and R. A. Lake Serologic Responses in Patients with Malignant Mesothelioma . Evidence for Both Public and Private Specificities Am. J. Respir. Cell Mol. Biol., May 1, 2000; 22(5): 550 - 556. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
